VHIO´s Clinical Research Program, incorporating multidisciplinary cancer teams, is dedicated to developing both novel agents directed to specific signaling pathways in cancer and new/redefined tools to diagnose cancer earlier and better predict response to treatment. We pioneer important studies involving both preclinical and early-drug development research studies and lead several phase I, II and III clinical trials designed to identify more effective, cancer therapies tailored to individual patients.